• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Fragmin (dalteparin sodium)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Fragmin (dalteparin sodium)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Fragmin (dalteparin sodium) is a low molecular weight heparin.

    Fragmin is specifically indicated for the following:

    • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction
    • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness
    • Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months
    • To reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients one month of age and older.

    Fragmin is supplied as an injection for subcutaneous administration. The recommended dose is weight based. Please see drug label.

    Clinical Results

    FDA Approval

    In adults, the efficacy of Fragmin was assessed in adults for the following:

    Prophylaxis of deep vein thrombosis in patients following hip replacement surgery, where Fragmin was compared with warfarin sodium and heparin. The incidence of deep vein thrombosis (DVT), as determined by evaluable venography, was significantly lower for the group treated with Fragmin compared with patients treated with warfarin sodium (two studies) and patients treated with heparin (1 study).

    Prophylaxis of Deep Vein Thrombosis following abdominal surgery in patients at risk for thromboembolic complications, where Fragmin was superior to placebo and similar to heparin in reducing the risk of DVT.

    Prophylaxis of Deep Vein Thrombosis in medical patients at risk for thromboembolic complications due to severely restricted mobility during acute illness, where Fragmin significantly reduced the incidence of thromboembolic reactions including verified DVT by Day 21 versus placebo.

    The efficacy of Fragmin in children was based on a single trial with 38 pediatric patients with symptomatic deep vein thrombosis and/or pulmonary embolism. Patients were treated with Fragmin for up to three months, with starting doses by age and weight. At study completion, 21 patients achieved resolution of the qualifying VTE, seven patients showed regression, two patients showed no change, no patients experienced progression of the VTE and one patient experienced recurrence of VTE.

    Side Effects

    Adverse effects associated with the use of Fragmin may include, but are not limited to, the following:

    hemorrhage

    thrombocytopenia (Type I)

    hematoma at the injection site

    pain at the injection site

    transient elevation of transaminases

    The label for Fragmin contains a boxed warning to alert health care professionals and patients that epidural or spinal hematomas (accumulation of blood that can mechanically compress the spinal cord) may occur in patients who are anticoagulated due to taking certain medications called low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia (injection near the spine) or undergoing spinal puncture (removing spinal fluid for testing). These hematomas may result in long-term or permanent paralysis. Health care professionals are advised to consider these risks when scheduling patients for spinal procedures as patients may be at a higher risk of developing VTE.

    Mechanism of Action

    Fragmin (dalteparin sodium) is a low molecular weight heparin.

    Additional Information

    For additional information regarding Fragmin or deep vein thrombosis and symptomatic venous thromboembolism, please visit the Fragmin drug label

    Approval Date: 1999-03-01
    Company Name: Pfizer
    Back to Listings

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing